Dexrazoxane Hydrochloride and Havrix Pediatric

• Generic Name: dexrazoxane
• Dosage Forms: n.a.
• Other Brand Names: Totect, Zinecard

Reduction of the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of ≥300 mg/m2 and would benefit from continued doxorubicin therapy (designated an orphan drug by FDA for this use).

Not recommended for use with initiation of doxorubicin therapy. (See Effectiveness of Cytotoxic Regimens under Cautions.)

• Generic Name: hepatitis a pediatric vaccine
• Dosage Forms: n.a.
• Other Brand Names: Havrix Pediatric, Vaqta Pediatric

Hepatitis is a serious disease caused by a virus. Hepatitis causes inflammation of the liver, vomiting, and jaundice (yellowing of the skin or eyes). Hepatitis can lead to liver cancer, cirrhosis, or death.

Hepatitis A is spread through contact with the stool (bowel movements) of a person infected with the hepatitis A virus. This usually occurs by eating food or drinking water that has become contaminated as a result of handling by an infected person.

The Havrix Pediatric is used to help prevent this disease in children.

This vaccine works by exposing your child to a small amount of the virus, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

Vaccination with Havrix Pediatric is recommended for all children who are 12 months of age or older. This vaccine is also recommended in children who travel to certain areas of the world where hepatitis A is a common disease.

Other risk factors for hepatitis in children include: receiving treatment for hemophilia or other bleeding disorders, or being in an area where there has been an outbreak of hepatitis A.

Like any vaccine, the Havrix Pediatric may not provide protection from disease in every person.